Allergan, Mimetogen partner to develop tavilermide topical dry eye treatment
As per the terms of the licensing deal, Allergan will fund phase 3 development of tavilermide. Mimetogen will receive an upfront payment of $50m from Allergan. The deal
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD. Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution